What is the right Mounjaro dose for diabetes?

How does Mounjaro dosing start when it's prescribed for type 2 diabetes?

The first pen contains 2.5 mg doses. That figure surprises some people who expect to feel an effect straightaway, but 2.5 mg is a settling-in dose, designed to reduce the nausea and digestive discomfort that can hit when GLP-1 receptor agonists are introduced too quickly. Most people stay at 2.5 mg for four weeks, then step to 5 mg, and if you want to understand what that transition involves, our guide to the Mounjaro 5 mg dose covers the common questions about that stage. From there, the prescriber reviews how blood sugar is tracking alongside tolerability before deciding whether to go further.

The full schedule of UK-licensed strengths runs 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. These aren't rungs you climb automatically, they're options your prescriber draws from, and many people find a dose below the maximum that works well for them without unnecessary side effects. If you want to understand what the full Mounjaro dose schedule looks like in practice, our guide covers the common questions.

Once you're established on a maintenance dose for diabetes, your prescriber will monitor HbA1c and body weight periodically. Tirzepatide's dual action on GIP and GLP-1 receptors means it influences both glucose regulation and appetite, a meaningful advantage for many people with type 2 diabetes who are also managing their weight, as noted in NICE's appraisal of tirzepatide.

What do clinical trials tell us about which diabetes doses work best?

The SURMOUNT and SURPASS clinical programmes together involved more than 10,000 participants across diabetes and obesity trials. Within the diabetes-focused SURPASS programme, higher doses of tirzepatide generally produced greater reductions in HbA1c and body weight, but the relationship isn't linear for every individual, and reaching the highest dose is not the aim in itself.

Published trial data show that 10 mg and 15 mg doses produced the largest average HbA1c reductions, but even 5 mg outperformed several comparators in clinical studies. What that means for you specifically depends on baseline HbA1c, kidney function, other medicines you take and whether GI side effects are limiting progression, and our page on Mounjaro type 2 diabetes dose goes into how prescribers weigh these factors. Your prescriber weighs all of this; trial averages are a useful backdrop, not a personal prescription.

If you're interested in how tirzepatide dosing compares when the clinical goal is weight management rather than diabetes control, the picture differs slightly, that page covers the weight-management licence separately.

What are the most common side effects as the diabetes dose increases?

GI effects dominate the early weeks: nausea, loose stools, constipation, indigestion and burping are the ones people mention most. They tend to peak shortly after a dose increase and ease within one to two weeks for most people, though not everyone. Fatigue and mild headache are also reported, particularly at the start.

More serious but much less common: pancreatitis. Severe stomach pain that radiates through to your back, with or without vomiting, needs urgent medical attention. The MHRA flagged acute pancreatitis as a known risk in a January 2026 Drug Safety Update for GLP-1 medicines, report any suspected side effects at the MHRA Yellow Card scheme.

If you're using oral contraceptives alongside tirzepatide, you'll need an additional non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide slows gastric emptying in a way that can reduce pill absorption. Tirzepatide is not recommended during pregnancy, while breastfeeding, or if you're trying to conceive, these situations need a direct conversation with your GP or specialist.

Where does your GP or specialist fit in alongside a private prescription?

If your type 2 diabetes is managed by your GP practice, they should know you're using tirzepatide regardless of whether the prescription comes through an NHS route or a private one. Tirzepatide interacts with the broader diabetes management plan, it can meaningfully lower blood glucose, and doses of insulin or sulphonylureas may need adjusting to avoid hypoglycaemia. That coordination sits with your prescribing GP or diabetes team.

On the NHS, tirzepatide for type 2 diabetes is prescribed where NICE criteria are met and local formulary decisions allow it. Access varies by area and practice. If you're considering the private route (either because you're waiting, or because NHS criteria don't apply to your situation) our Mounjaro overview explains how a private prescription works and what the clinical assessment involves. Our prescribers notify your GP in line with GPhC guidance as standard, so your diabetes care team is kept informed. For more on how the consultation is structured, our clinical team page sets out who reviews your information.

If you're ready to take the next step, you can start your free consultation and have your answers reviewed the same day by a GPhC-registered prescriber. The pen that arrives (in plain, unbranded packaging via DPD, with a tracking link to your phone) is exactly the same KwikPen dispensed through any legitimate UK pharmacy. The difference is there's no waiting list.